Post hoc analysis of 2 phase 3 trials in moderately to severely active ulcerative colitis (n=1162): week-12 clinical response with mirikizumab was 69.8% with no prior advanced therapy failure, 63.9% after 1, 45.3% after 2 or more and 41.9% in difficult-to-treat disease.
Secondary analysisn = 1,162
Hart et al. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis